What is MiRXES?
Founded in 2014, MiRXES is a homegrown biotech firm headquartered in Singapore, specializing in the discovery and incubation of microRNA-based applications across medical, pharmaceutical, agricultural, and veterinary industries. Leveraging a world-leading microRNA research and technology platform, the company develops innovative microRNA biomarker profiling and applicative uses to address real-world challenges. With established R&D and manufacturing facilities in Singapore, China, and the US, MiRXES is dedicated to building a global microRNA ecosystem, fostering collaborations with clinicians, researchers, and corporations to translate scientific advancements into accessible and affordable solutions for disease eradication and life improvement.
How much funding has MiRXES raised?
MiRXES has raised a total of $167M across 3 funding rounds:
Series C
$77M
Series D
$50M
Debt
$40M
Series C (2021): $77M with participation from CR-CP Life Science Fund, Rock Springs Capital, and EDBI
Series D (2023): $50M led by Mitsui & Co., Fupu Investment Management, and NHH Venture Fund
Debt (2025): $40M supported by CBC Group
Key Investors in MiRXES
Mitsui & Co.
Mitsui & Co. is a global trading and investment company with a diverse portfolio across multiple industries, focusing on supporting industry growth, promoting energy transition, and enhancing quality of life through healthcare solutions.
CBC Group
CBC Group is a major healthcare-focused investment firm in Asia, specializing in pharmaceutical & biotech, medtech, and healthcare services, aiming to drive transformative changes and sustainable growth within the sector.
Rock Springs Capital
Rock Springs Capital is an investment firm that likely focuses on the healthcare and biotechnology sectors, providing capital to companies advancing innovative medical solutions.
What's next for MiRXES?
The substantial enterprise-level financing positions MiRXES for accelerated expansion and continued innovation in the competitive biotech landscape. This strategic backing is expected to fuel further development of its microRNA platform, enhance its global R&D and manufacturing capabilities, and support the commercialization of its groundbreaking solutions. The company's focus on transforming scientific discoveries into affordable, accurate, and accessible healthcare products indicates a strong commitment to improving global health outcomes, suggesting a future driven by strategic partnerships and market penetration.
See full MiRXES company page
